The effect of oral melatonin on the quality of life, sleep and blood pressure of hemodialysis patients: a randomized clinical trial
Abstract Background Considering the effect of melatonin on the quality of life and sleep in various diseases such as cancer, in the present study, the effect of melatonin was investigated on the quality of life, sleep, and blood pressure of hemodialysis patient. Methods This study was conducted as a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-025-04387-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Background Considering the effect of melatonin on the quality of life and sleep in various diseases such as cancer, in the present study, the effect of melatonin was investigated on the quality of life, sleep, and blood pressure of hemodialysis patient. Methods This study was conducted as a double-blind clinical trial. The patients were randomly divided into two groups of 41 people receiving 3 mg of oral melatonin or placebo at night for six weeks. After taking written informed consent, all patients completed demographic, Pittsburgh Sleep Quality Index (PSQI), and Kidney Disease Quality of Life Questionnaire-Short Form (KDQOL-SF) questionnaires. The nurse of dialysis ward measured and recorded systolic and diastolic blood pressure in all patients during dialysis. At the end of the study, the questionnaires were completed again by the patients, and their blood pressure was measured and re-recorded. The data was statistically analyzed using SPSS software 24. Results Mean age of patients in melatonin and placebo group was 48.97 ± 9.77 and 50.07 ± 12.65, respectively (p = 0.661). There was no statistically difference between two groups regarding gender distribution (p = 0.64) and Body mass index (p = 0.15), duration of hemodialysis (p = 0.54), systolic blood pressure (p = 0.7), diastolic blood pressure (p = 0.13), PSQI score (p = 0.73) and KDQOL-SF score in all domains (p > 0.05) before intervention. After intervention, there was no significant difference between two groups regarding systolic blood pressure (p = 0.83) and diastolic blood pressure (p = 0.21, but PSQI score (p = 0.0001) was significantly different between two groups. KDQOL-SF score in kidney disease domains was significantly different between two groups only in sleep domain (p = 0.003). Conclusions The present study showed that melatonin improves sleep quality but only sleep domain, physical function and energy domains of quality of life improved. There was no significant change in the blood pressure of the patients. It is recommended to conduct more studies with longer duration melatonin use for assessing its effect on quality of life and check 24- hour ambulatory blood pressure for precise assessment of melatonin effect on blood pressure. Trial registration IRCT20230205057333N1, Date of registration: 2023/03/15, Available at http://www.irct.behdasht.gov.ir . |
|---|---|
| ISSN: | 1471-2369 |